Expect more from your RNA analyses
Low quality samples shouldn’t mean low quality results.
RNA sequencing is being recognized as a technology of choice for fusion detection but often, input amount and sample quality can impact the downstream results. RNAtarget Technology by SOPHiA GENETICS is an advanced customizable RNA-based sequencing approach that offers a single convenient workflow with confident novel fusion detection, while also providing ability to detect SNV/Indels and expression changes.
Novel fusion detection with high sensitivity
Optimized for small FFPE samples using 10ng RNA minimum input
Customizable gene content to perfectly fit the needs of each laboratory
Automation-friendly, streamlined 1.5-day workflow
Detection of SNV/Indels and expression changes in selected genes
Streamlined visualisation and interpretation with the SOPHiA DDM™
Benefit from sensitive novel fusion detection
Fully-guided amplicon-based solutions can limit the fusion genes detectable by the assay, potentially leading to false negative results. The capture-based design of RNAtarget Technology matches technical sensitivity of fully-guided amplicon-based solutions with 10ng of input while being able to detect more fusions due to novel fusion detection capability.
|RNAtarget Technology||Amplicon (fully-guided)||Amplicon (single-primer)|
|Novel fusion detection||✓||X||✓|
|Low amount / low quality input||✓||✓||X|
Figure 1: Based on analysis of SeraCare and Horizon Discovery reference standards, RNAtarget Technology detects additional fusions (CD74-ROS1, EGFR-SEPT14, METex14 and SLC34A2-ROS1) that are not detected by an amplicon solution. Please note that both panels are designed to detect all fusions shown due to partner-agnostic panel design. Data on file.
Experience highly performant fusion detection with minimal sample input
RNAtarget Technology can detect more fusions in minimal input material samples (20ng) compared to a standard amplicon-based (single-primer) solutions with novel fusion detection capabilities (Figure 1).
Maximize insights from precious biopsy samples
RNAtarget Technology also detects SNVs/Indels in RNA which can be beneficial in cases where biopsy samples are too small to be processed with a separate DNA workflow. SNV/Indel calling in RNA also provides an indication of the expression and thus, of biological relevance of the detected mutation. Additionally, RNAtarget Technology allows for expression level assessment to provide insights into promoter fusions and confirmation of CNV calls.
Results are displayed in SOPHiA DDM™. The platform allows immediate focus on relevant genomic alterations with several features facilitating the interpretation process:
- Fusion display and flagging
- SNV/Indel display and flagging
- Enhanced downloadable quality report with important indicators like control gene molecule coverage, group size (based on PASS variants), and on-target and on-flank bases
|Other solutions||RNAtarget Technology|
|Panel design and onboarding||
|Nucleic acid extraction||
|Library prep and capture||
|Analysis and visualization||
|Annotation and reporting||
|Sample Type||FFPE, fresh frozen tissue|
|Input Type||RNA or TNA|
|Input Amount||10-200 ng, 50 ng recommended|
|Library Preparation Time||1.5 days|
|Analysis Time From FASTQ File||8h/16 sample batch|
Please fill out the form below to get in touch
SOPHiA DDM™ for Solid Tumors
From targeted to comprehensive genomic profiling, our solutions support healthcare professionals in their journey to analyze solid tumors.
NGS Detection of Gene Fusions
SOPHiA DDM™ supports gene fusion detection, annotation, interpretation, and reporting for multiple available panels, without compromising analytical sensitivity.